Consolidated Statement of Comprehensive Income for the year ended 31 December

	Notes	2024 \$m	2023 \$m	2022 \$m
Product Sales	1	50,938	43,789	42,998
Alliance Revenue	1	2,212	1,428	755
Collaboration Revenue	1	923	594	598
Total Revenue		54,073	45,811	44,351
Cost of sales		(10,207)	(8,268)	(12,391)
Gross profit	1	43,866	37,543	31,960
Distribution expense		(555)	(539)	(536)
Research and development expense	2	(13,583)	(10,935)	(9,762)
Selling, general and administrative expense	2	(19,977)	(19,216)	(18,419)
Other operating income and expense	2	252	1,340	514
Operating profit		10,003	8,193	3,757
Finance income	3	458	344	95
Finance expense	3	(1,742)	(1,626)	(1,346)
Share of after tax losses in associates and joint ventures	11	(28)	(12)	(5)
Profit before tax		8,691	6,899	2,501
Taxation	4	(1,650)	(938)	792
Profit for the period		7,041	5,961	3,293
Other comprehensive income:				
Items that will not be reclassified to profit and loss:				
Remeasurement of the defined benefit pension liability	22	80	(406)	1,118
Net gains/(losses) on equity investments measured at fair value through Other comprehensive income		139	278	(88)
Fair value movements related to own credit risk on bonds designated as fair value through profit or loss		12	(6)	2
Tax on items that will not be reclassified to profit and loss	4	(43)	101	(216)
		188	(33)	816
Items that may be reclassified subsequently to profit and loss:				
Foreign exchange arising on consolidation	23	(957)	608	(1,446)
Foreign exchange arising on designated liabilities in net investment hedges	23	(122)	24	(282)
Fair value movements on cash flow hedges		(129)	266	(97)
Fair value movements on cash flow hedges transferred to profit and loss		177	(145)	73
Fair value movements on derivatives designated in net investment hedges	23	39	44	(8)
Costs of hedging		(21)	(19)	(7)
Tax on items that may be reclassified subsequently to profit and loss	4	25	(12)	73
		(988)	766	(1,694)
Other comprehensive (expense)/income for the period, net of tax		(800)	733	(878)
Total comprehensive income for the period		6,241	6,694	2,415
Profit attributable to:				
Owners of the Parent		7,035	5,955	3,288
Non-controlling interests	26	6	6	5
Total comprehensive income attributable to:				
Owners of the Parent		6,236	6,688	2,413
Non-controlling interests	26	5	6	2
Basic earnings per \$0.25 Ordinary Share	5	\$4.54	\$3.84	\$2.12
Diluted earnings per \$0.25 Ordinary Share	5	\$4.50	\$3.81	\$2.11
Weighted average number of Ordinary Shares in issue (millions)	5	1,550	1,549	1,548
Diluted weighted average number of Ordinary Shares in issue (millions)	5	1,563	1,562	1,560
Dividends declared and paid in the pariod	25	4.602	1 107	1 105
Dividends declared and paid in the period		4,602	4,487	4,485

All activities were in respect of continuing operations.

\$m means millions of US dollars.

Consolidated Statement of Financial Position

at 31 December

	Notes	2024 \$m	2023 \$m	2022 \$m
Assets	140103	ψ	Ψ	Ψ
Non-current assets				
Property, plant and equipment	7	10,252	9,402	8,507
Right-of-use assets	8	1,395	1,100	942
Goodwill	9	21,025	20,048	19,820
Intangible assets	10	37,177	38,089	39,307
Investments in associates and joint ventures	11	268	147	76
Other investments	12	1,632	1,530	1,066
Derivative financial instruments	13	182	228	74
Other receivables	14	930	803	835
Deferred tax assets	4	5,347	4,718	3,263
		78,208	76,065	73,890
Current assets		,	-	
Inventories	15	5,288	5,424	4,699
Trade and other receivables	16	12,972	12,126	10,521
Other investments	12	166	122	239
Derivative financial instruments	13	54	116	87
Income tax receivable		1,859	1,426	731
Cash and cash equivalents	17	5,488	5,840	6,166
Assets held for sale	18	_		150
		25,827	25,054	22,593
		104,035	101,119	96,483
Liabilities		,	,	
Current liabilities				
Interest-bearing loans and borrowings	19	(2,337)	(5,129)	(5,314)
Lease liabilities	8	(339)	(271)	(228)
Trade and other payables	20	(22,465)	(22,374)	(19,040)
Derivative financial instruments	13	(50)	(156)	(93)
Provisions	21	(1,269)	(1,028)	(722)
Income tax payable		(1,406)	(1,584)	(896)
		(27,866)	(30,542)	(26,293)
Non-current liabilities		(==,===,	(5-7	(=======
Interest-bearing loans and borrowings	19	(26,506)	(22,365)	(22,965)
Lease liabilities	8	(1,113)	(857)	(725)
Derivative financial instruments	13	(115)	(38)	(164)
Deferred tax liabilities	4	(3,305)	(2,844)	(2,944)
Retirement benefit obligations	22	(1,330)	(1,520)	(1,168)
Provisions	21	(921)	(1,127)	(896)
Income tax payable		(238)	-	
Other payables	20	(1,770)	(2,660)	(4,270)
		(35,298)	(31,411)	(33,132)
Total liabilities		(63,164)	(61,953)	(59,425)
Net assets		40,871	39,166	37,058
Equity		,		· · ·
Capital and reserves attributable to equity holders of the Company				
Share capital	24	388	388	387
Share premium account		35,226	35,188	35,155
Capital redemption reserve		153	153	153
Merger reserve		448	448	448
Other reserves	23	1,411	1,464	1,468
Retained earnings	23	3,160	1,502	(574)
	20	40,786	39,143	37,037
Non-controlling interests	26	85	23	21
Total equity	20	40,871	39,166	37,058
- I van oquity		40,071	55,100	57,000

The Financial Statements from pages 148 to 218 were approved by the Board and were signed on its behalf by

Pascal Soriot Director

Aradhana Sarin Director

6 February 2025

Consolidated Statement of Financial Position

Consolidated Statement of Changes in Equity for the year ended 31 December

	Share capital \$m	Share premium r account \$m	Capital redemption reserve \$m	Merger reserve \$m	Other reserves \$m	Retained earnings \$m	Total attributable to owners \$m	Non- controlling interests \$m	Total equity \$m
At 1 January 2022	387	35,126	153	448	1,444	1,710	39,268	19	39,287
Profit for the period	-	-	-	-	-	3,288	3,288	5	3,293
Other comprehensive expense ¹	_	_	_	_	_	(875)	(875)	(3)	(878)
Transfer to other reserves ²	_	_	_	_	24	(24)	_	_	_
Transactions with owners									
Dividends (Note 25)	_	_	_	_	_	(4,485)	(4,485)	_	(4,485)
Issue of Ordinary Shares	-	29	-	-	-	-	29	_	29
Share-based payments charge for the period (Note 29)	_	_	_	_	-	619	619	_	619
Settlement of share plan awards	_	_	_	_	_	(807)	(807)	_	(807)
Net movement	-	29	_	_	24	(2,284)	(2,231)	2	(2,229)
At 31 December 2022	387	35,155	153	448	1,468	(574)	37,037	21	37,058
Profit for the period	-	-	-	_	-	5,955	5,955	6	5,961
Other comprehensive income ¹	-	_	-	_	-	733	733	_	733
Transfer to other reserves ²	_	_	_	_	(4)	4	_	_	_
Transactions with owners									
Dividends (Note 25)	_	_	-	_	_	(4,487)	(4,487)	_	(4,487)
Dividends paid to non-controlling interests (Note 25)	_	_	_	_	_	_	_	(4)	(4)
Issue of Ordinary Shares	1	33	-	-	-	-	34	_	34
Share-based payments charge for the period (Note 29)	-	-	-	-	-	579	579	-	579
Settlement of share plan awards	-	-	-	-	-	(708)	(708)	_	(708)
Net movement	1	33	-	_	(4)	2,076	2,106	2	2,108
At 31 December 2023	388	35,188	153	448	1,464	1,502	39,143	23	39,166
Profit for the period	-	-	-	-	-	7,035	7,035	6	7,041
Other comprehensive expense ¹	-	-	-	-	-	(799)	(799)	(1)	(800)
Transfer to other reserves ²	_	-	-	_	15	(15)	_	_	-
Transactions with owners									
Dividends (Note 25)	-	-	-	-	-	(4,602)	(4,602)	-	(4,602)
Dividends paid to non-controlling interests (Note 25)	-	-	-	-	-	-	_	(4)	(4)
Issue of Ordinary Shares	-	38	-	-	-	-	38	-	38
Changes in non-controlling interests	-	-	-	-	-	-	-	61	61
Movement in shares held by Employee Benefit Trusts ²	-	-	-	-	(68)	-	(68)	_	(68)
Share-based payments charge for the period (Note 29)	-	-	-	-	-	660	660	-	660
Settlement of share plan awards	-	-	_	-	_	(621)	(621)	-	(621)
Net movement	-	38	_	-	(53)	1,658	1,643	62	1,705
At 31 December 2024	388	35,226	153	448	1,411	3,160	40,786	85	40,871

¹ Included within Other comprehensive expense of \$800m (2023: income of \$733m; 2022: expense of \$878m) is a charge of \$21m (2023: \$19m; 2022: \$7m), relating to Costs of hedging.
2 Amounts charged or credited to other reserves relate to exchange adjustments arising on goodwill and movements in shares held by Employee Benefit Trusts.

Consolidated Statement of Cash Flows for the year ended 31 December

	Notes	2024 \$m	2023 \$m	2022 \$m
Cash flows from operating activities		·		
Profit before tax		8,691	6,899	2,501
Finance income and expense	3	1,284	1,282	1,251
Share of after tax losses of associates and joint ventures	11	28	12	5
Depreciation, amortisation and impairment		6,688	5,387	5,480
Increase in trade and other receivables		(1,624)	(1,425)	(1,349)
(Increase)/decrease in inventories		(131)	(669)	3,941
Increase in trade and other payables and provisions		862	2,394	1,165
Gains on disposal of intangible assets	2	(64)	(251)	(104)
Fair value movements on contingent consideration arising from business combinations	20	311	549	82
Non-cash and other movements	17	(121)	(386)	(692)
Cash generated from operations		15,924	13,792	12,280
Interest paid		(1,313)	(1,081)	(849)
Tax paid		(2,750)	(2,366)	(1,623)
Net cash inflow from operating activities		11,861	10,345	9,808
Cash flows from investing activities				
Acquisition of subsidiaries, net of cash acquired	27	(2,771)	(189)	(48)
Payments upon vesting of employee share awards attributable to business combinations	27	(3)	(84)	(215)
Payment of contingent consideration from business combinations	20	(1,008)	(826)	(772)
Purchase of property, plant and equipment		(1,924)	(1,361)	(1,091)
Disposal of property, plant and equipment		55	132	282
Purchase of intangible assets		(2,662)	(2,417)	(1,480)
Disposal of intangible assets		123	291	447
Movement in profit-participation liability	2	-	190	_
Purchase of non-current asset investments		(96)	(136)	(45)
Disposal of non-current asset investments		78	32	42
Movement in short-term investments, fixed deposits and other investing instruments		30	97	(114)
Payments to associates and joint ventures	11	(158)	(80)	(26)
Disposal of investments in associates and joint ventures		13	_	
Interest received		343	287	60
Net cash outflow from investing activities		(7,980)	(4,064)	(2,960)
Net cash inflow before financing activities		3,881	6,281	6,848
Cash flows from financing activities				
Proceeds from issue of share capital		38	33	29
Own shares purchased by Employee Benefit Trusts		(81)	_	
Issue of loans and borrowings		6,492	3,816	
Repayment of loans and borrowings		(4,652)	(4,942)	(1,271)
<u>Dividends paid</u>	25	(4,629)	(4,481)	(4,364)
Hedge contracts relating to dividend payments	25	16	(19)	(127)
Repayment of obligations under leases		(316)	(268)	(244)
Movement in short-term borrowings		(31)	161	74
Payment of Acerta Pharma share purchase liability		(833)	(867)	(920)
Net cash outflow from financing activities		(3,996)	(6,567)	(6,823)
Net (decrease)/increase in Cash and cash equivalents in the period		(115)	(286)	25
Cash and cash equivalents at the beginning of the period		5,637	5,983	6,038
Exchange rate effects		(93)	(60)	(80)
Cash and cash equivalents at the end of the period	17	5,429	5,637	5,983